Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Additional Alemtuzumab Course in RRMS Patients With Disease Activity After Two Prior Courses
2016-000464-42Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Sanofi. Primary endpoint: Change in neurological examination (Confirmed relapse[s]). Started Apr 2016; status: completed.
02
Drugs
alemtuzumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2016-000464-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000464-42.